Ipamorelin
A selective GH secretagogue. We read all 51 studies. The protocol is below.
Free — puts Ipamorelin on your decision board.
Everything you need to start: dose, sourcing, safety, our verdict.
One purchase · yours forever
Built from 51 cited studies.
- **what's actually in your vial is the CJC + ipamorelin stack** — ipamorelin alone is the smaller compounded order; the IGF-1 elevation is additive and the chronic-monitoring story applies to the stack, not either peptide alone
- you're on TRT and considering adding a GH peptide — the "cleanest" GHRP profile (no cortisol/prolactin spike) is the one real differentiator vs GHRP-2/6, but "cleanest" ≠ safe
- you're a postmenopausal woman whose tele-clinic just added it to your "longevity" stack and you want to know what you're paying for
- you have active or recent cancer — the chronic-IGF-1 question still applies, even to the cleanest GHRP
- you compete in a tested sport — WADA-banned
- the "gentle starter" marketing line sold you on a once-weekly schedule — **real protocol is 1–3 subq injections per day, every day, indefinitely**
- you're a healthy adult expecting "anti-aging" results the trials don't support
- IGF-1 climbs above ~300 ng/mL (cancer-risk territory at the upper end).
- Significant water retention or new carpal-tunnel-style symptoms.
- New or worsening insulin resistance (fasting glucose creep).
- 12 weeks with no IGF-1 movement and no subjective change.
What it is.
Ipamorelin is a five-amino-acid that tells the pituitary to release a pulse of growth hormone. It's a GH secretagogue — it doesn't replace GH, it asks the body to make its own.
What made it famous in the late 1990s is that it's selective. Older secretagogues like GHRP-6 also pushed up cortisol and prolactin. Ipamorelin doesn't, at standard doses. That's the entire pitch in one sentence.
It's almost always paired with CJC-1295, a GHRH analog that lengthens the pulse. The combo is the most-prescribed in compounding pharmacies in the US. Sold as online and via pharmacies on prescription.
WADA-banned in and out of competition. If you compete in anything sanctioned, this ends your career.
TL;DR. 30-second version.
The compressed verdict — what Ipamorelin actually is, what the human evidence shows, and the watch-for in three bullets. Locked.
Get the report · $19 ↓Mechanism.
How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.
Get the report · $19 ↓Evidence. What we actually know in humans.
The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.
Get the report · $19 ↓Dose. The actual protocol.
The specific protocol — dose, titration schedule, cycle pattern, frequency, route.
Sourcing. Where the cohort actually buys.
Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.
Safety. Side effects.
The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.
Get the report · $19 ↓Editorial position.
Our editorial position — explicit yes / no / depends, with the reasoning behind it.
Get the report · $19 ↓Citations.
- 01Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews. 2026;10(1). PMID: 41490200.
- 02Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine. 2026;54(1):223-229. PMID: 41476424.
- 03Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology. 1998;139(5):552-61. PMID: 9849822.
- 04Johansen PB, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999;9(2):106-13. PMID: 10373343.
- 05Gouda M, et al. The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. Animal reproduction science. 2024;268:107550. PMID: 38996787.
+Show all 51 citationsShow fewer citations
- 06Lu Z, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior. 2024;284:114644. PMID: 39043357.
- 07Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical research. 1999;16(9):1412-6. PMID: 10496658.
- 08Venkova K, et al. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. The Journal of pharmacology and experimental therapeutics. 2009;329(3):1110-6. PMID: 19289567.
- 09Andersen NB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2001;11(5):266-72. PMID: 11735244.
- 10Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology. 2020;9(Suppl 2):S149-S159. PMID: 32257855.
- 11Jiménez-Reina L, et al. Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology. 2002;17(3):707-14. PMID: 12168778.
- 12Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Xenobiotica; the fate of foreign compounds in biological systems. 1998;28(11):1083-92. PMID: 9879640.
- 13Greenwood-Van Meerveld B, et al. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. Journal of experimental pharmacology. 2012;4:149-55. PMID: 27186127.
- 14Ankersen M, et al. A new series of highly potent growth hormone-releasing peptides derived from ipamorelin. Journal of medicinal chemistry. 1998;41(19):3699-704. PMID: 9733495.
- 15Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. The Journal of endocrinology. 2000;165(3):569-77. PMID: 10828840.
- 16Beck DE, et al. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International journal of colorectal disease. 2014;29(12):1527-34. PMID: 25331030.
- 17Adeghate E, et al. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro endocrinology letters. 2004;25(6):403-6. PMID: 15665799.
- 18Hansen TK, et al. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorganic & medicinal chemistry letters. 2001;11(14):1915-8. PMID: 11459660.
- 19Semenistaya E, et al. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug testing and analysis. 2015;7(10):919-25. PMID: 25869809.
- 20N Mohammadi E, et al. Attenuation of Visceral and Somatic Nociception by Ghrelin Mimetics. Journal of experimental pharmacology. 2020;12:267-274. PMID: 32801950.
- 21Krug O, et al. Analysis of new growth promoting black market products. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2018;41:1-6. PMID: 29864719.
- 22Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 2009;19(5):426-31. PMID: 19231263.
- 23Lall S, et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications. 2001;280(1):132-8. PMID: 11162489.
- 24Hansen TK, et al. Novel orally active growth hormone secretagogues. Journal of medicinal chemistry. 1998;41(19):3705-14. PMID: 9733496.
- 25Ferro P, et al. Structure-activity relationship for peptídic growth hormone secretagogues. Drug testing and analysis. 2017;9(1):87-95. PMID: 26811125.
- 26Gajda PM, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug testing and analysis. 2019;11(2):350-354. PMID: 30136411.
- 27Shimatsu A. [Ghrelin-related drugs: clinical perspectives]. Nihon rinsho. Japanese journal of clinical medicine. 2004;62 Suppl 9:435-8. PMID: 15506422.
- 28Minamitake Y. [Structure-activity relationship of ghrelin]. Nihon rinsho. Japanese journal of clinical medicine. 2004;62 Suppl 9:328-31. PMID: 15506395.
- 29Tsivou M, et al. Doping control container for urine stabilization: a pilot study. Drug testing and analysis. 2017;9(5):699-712. PMID: 27497113.
- 30Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports medicine (Auckland, N.Z.). 2026. PMID: 41966639.
- 31Worm DJ, et al. A stable meta-carborane enables the generation of boron-rich peptide agonists targeting the ghrelin receptor. Journal of peptide science : an official publication of the European Peptide Society. 2018;24(10):e3119. PMID: 30168238.
- 32Ahnfelt-Rønne I, et al. Do growth hormone-releasing peptides act as ghrelin secretagogues?. Endocrine. 2001;14(1):133-5. PMID: 11322495.
- 33Thomas A, et al. Metabolism of growth hormone releasing peptides. Analytical chemistry. 2012;84(23):10252-9. PMID: 23101768.
- 34Mavrych V, et al. Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in aging. 2026;7:1790247. PMID: 42021992.
- 35Semenistaya E, et al. Solid-phase extraction of small biologically active peptides on cartridges and microelution 96-well plates from human urine. Drug testing and analysis. 2016;8(9):940-9. PMID: 26472487.
- 36Johansen PB, et al. Growth hormone (GH) hypersecretion and GH receptor resistance in streptozotocin diabetic mice in response to a GH secretagogue. Experimental diabesity research. 2003;4(2):73-81. PMID: 14630569.
- 37Renke G, et al. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. International journal of molecular sciences. 2026;27(9). PMID: 42123471.
- 38Cox HD, et al. Detection of GHRP-2 and GHRP-6 in urine samples from athletes. Drug testing and analysis. 2015;7(5):439-44. PMID: 25809000.
- 39Matsumoto M, et al. Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues. Biochemical and biophysical research communications. 2001;284(3):655-9. PMID: 11396951.
- 40Fowkes MM, et al. Peptidomimetic growth hormone secretagogue derivatives for positron emission tomography imaging of the ghrelin receptor. European journal of medicinal chemistry. 2018;157:1500-1511. PMID: 30282322.
- 41Hansen BS, et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. European journal of endocrinology. 1999;141(2):180-9. PMID: 10427162.
- 42Thomas A, et al. Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry. Journal of separation science. 2016;39(2):333-41. PMID: 26578461.
- 43Malmlöf K, et al. Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. 1999;9(6):445-50. PMID: 10629165.
- 44Chan CB, et al. Stimulation of growth hormone secretion from seabream pituitary cells in primary culture by growth hormone secretagogues is independent of growth hormone transcription. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. 2004;139(1-3):77-85. PMID: 15556068.
- 45Yeung CM, et al. Seabream ghrelin: cDNA cloning, genomic organization and promoter studies. The Journal of endocrinology. 2006;189(2):365-79. PMID: 16648303.
- 46Kwok WH, et al. Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. Analytical and bioanalytical chemistry. 2013;405(8):2595-606. PMID: 23318763.
- 47Thomas A, et al. Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Analytical and bioanalytical chemistry. 2011;401(2):507-16. PMID: 21298258.
- 48Thomas A, et al. Determination of prohibited, small peptides in urine for sports drug testing by means of nano-liquid chromatography/benchtop quadrupole orbitrap tandem-mass spectrometry. Journal of chromatography. A. 2012;1259:251-7. PMID: 22901302.
- 49Timms M, et al. A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography. Drug testing and analysis. 2014;6(10):985-95. PMID: 24574167.
- 50Coutinho LFD, et al. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness. 2026. PMID: 41880199.
- 51Peschke B, et al. The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. European journal of medicinal chemistry. 2002;37(6):487-501. PMID: 12204475.
Everything you need to start.
Dose, sourcing, safety, our verdict. One purchase. Yours forever.
Built from 51 cited studies.